Reported positive interim data from Phase 3 open-label SHORELINE Study showing that more than 70% of patients successfully treated with zuranolone 30 mg needed two or fewer treatment courses over one ...
Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) rose sharply in today's pre-market trading after the company confirmed the receipt of Biogen’s nonbinding $7.22/share acquisition proposal. Sage ...
Downtown Sarasota's Sage recently began selling bottled versions of some of its cocktails, letting you bring home the flavors of the restaurant's popular bar. To make them, the restaurant is using a ...
In November, Biogen (NASDAQ: BIIB) agreed to pay Sage Therapeutics (NASDAQ: SAGE) $1.5 billion for rights to its depression drug zuranolone and an early-stage candidate treatment for tremors. It's an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results